ArticleFrontiers in immunology2012
The Role of the PI3K Signaling Pathway in CD4(+) T Cell Differentiation and Function.
Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02721719 (The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis), which is not on this map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- A systematic review and meta-analysis on the regulation of programmed cell death-1 on T-cells in type 2 diabetes.Medicine · 2021Pooled it
- A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4+ T cell signaling and differentiation.The Journal of experimental medicine · 2026Article
- Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy.Materials today. Bio · 2026Article
- Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma.Molecular therapy. Methods & clinical development · 2025Article
- Metabolic engineering to facilitate anti-tumor immunity.Cancer cell · 2025Article
- FAS(APO), DAMP, and AKT Phosphoproteins Expression Predict the Development of Nosocomial Infection After Pediatric Burn Injury.Journal of burn care & research : official publication of the American Burn Association · 2024Article
- Inhibitory co-receptor Lag3 supports Foxp3Immunity · 2024Article
- Quantitative characterization of immune cells by measuring cellular signal transduction pathway activity.Scientific reports · 2024Article
- Obese visceral adipose dendritic cells downregulate regulatory T cell development through IL-33.Frontiers in immunology · 2024Article
- Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies.Frontiers in pharmacology · 2024Article
- Compartment-driven imprinting of intestinal CD4 T cells in inflammatory bowel disease and homeostasis.Clinical and experimental immunology · 2023Article
- Site-Selective Functionalized PD-1 Mutant for a Modular Immunological Activity against Cancer Cells.Biomacromolecules · 2023Article
- Age-dependent transcriptomic profiles of leukocytes in pediatric population.Clinical immunology (Orlando, Fla.) · 2023Article
- AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival.Journal for immunotherapy of cancer · 2023Article
- Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.Journal of translational medicine · 2023Article
- Article
- Expression Profile of miRNA from High, Middle, and Low Stress-Responding Sheep during Bacterial Endotoxin Challenge.Animals : an open access journal from MDPI · 2023Article
- The magic of small-molecule drugs duringFrontiers in immunology · 2023Review
- A panel of blood-based circulatory miRNAs with diagnostic potential in patients with psoriasis.Frontiers in medicine · 2023Article
- Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment.Frontiers in immunology · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relative activity of regulatory versus conventional CD4(+) T cells ultimately maintains the delicate balance between immune tolerance and inflammation. At the molecular level, the activity of phosphatidylinositol 3-kinase (PI3K) and its downstream positive and negative regulators has a major role in controlling the balance between immune regulation and activation of different subsets of effector CD4(+) T cells. In contrast to effector T cells which require activation of the PI3K to differentiate and mediate their effector function, regulatory T cells rely on minimal activation of this pathway to develop and maintain their characteristic phenotype, function, and metabolic state. In this review, we discuss the role of the PI3K signaling pathway in CD4(+) T cell differentiation and function, and focus on how modulation of this pathway in T cells can alter the outcome of an immune response, ultimately tipping the balance between tolerance and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.